Acquisition adds Franklin solution, an AI-powered cloud platform for clinical decision support in genetic diseases
Strengthens QIAGEN Digital Insights offering for small and mid-sized labs worldwide with easy-to-use, fast and flexible NGS data interpretation in a rapidly growing market
Franklin complements QCI Interpret, QCI Precision Insights and QIAGEN’s leading genetic databases COSMIC and HGMD
QIAGEN announced it has signed a definitive agreement to acquire Genoox, a provider of AI-powered software that enables clinical labs to scale and accelerate the processing of complex genetic tests.
Genoox was founded in 2014 by Amir Trabelsi and Moshe Einhorn later joined by Yuval Porat and Oron Lev . The company has raised $26 million from Glilot Capital Partners, TriVentures, Inimiti, IMED, The Group Ventures, Artofin, and IN Ventures.
The acquisition adds Franklin, Genoox’s flagship cloud-based platform, to the QIAGEN Digital Insights (QDI) portfolio, strengthening QIAGEN’s leadership in bioinformatics for clinical genomics applications.
Franklin is ideally suited for small to mid-sized laboratories performing genetic testing, particularly for inherited diseases. It empowers labs to analyze next-generation sequencing (NGS) data – from targeted gene panels to whole exome and genome sequencing (WES/WGS) – and delivers real-time, AI-driven insights to support clinical decision-making. Applications range from diagnosing genetic disorders and informing cancer treatments to supporting family planning decisions.
The platform is currently used by more than 1,700 healthcare organizations in over 50 countries and has powered more than 150,000 case interpretations to date.
“The acquisition of Genoox brings together two complementary strengths to better serve clinical testing laboratories,” said Thierry Bernard, CEO of QIAGEN. “Franklin’s AI-powered solution offers exciting opportunities for labs to rapidly identify the most clinically relevant insights and help improve patient outcomes. Combined with QIAGEN’s trusted clinical knowledge and interpretation tools, the addition of Franklin to our portfolio will enable QIGEN to better address the challenges of our customers who are seeking easy-to-use, rapid and scalable clinical decision-support solutions.”
“Joining QIAGEN marks a major milestone in our mission to make genomic data more accessible and impactful,” said Amir Trabelsi, Co-founder and CEO of Genoox. “Franklin will benefit from QIAGEN’s global reach and scientific leadership as we scale to support more labs and patients around the world. As part of QIAGEN, we can together drive the next wave of precision medicine.”
The acquisition also creates a path to integrate QIAGEN’s genomic content into the Franklin platform. This includes the Human Gene Mutation Database (HGMD), the Catalogue of Somatic Mutations in Cancer (COSMIC), and the QIAGEN Knowledge Base (QKB) – all of which power the company’s leading QCI Interpret and QCI Precision Insights solutions. These future integrations will expand Franklin’s interpretive power, and in turn improving diagnostic yield, turnaround time and scalability for clinical labs.
Transaction summary
QIAGEN has acquired Genoox for $80 million – $70 million in cash and eligible for additional milestone payments of up to $10 million. The acquisition is expected in 2025 to generate approximately $5 million of sales for QIAGEN and have a neutral impact on adjusted EPS.
Credit: Genoox
